Risks To Shareholder Returns Are Elevated At These Prices For Merit Medical Systems, Inc. (NASDAQ:MMSI)

With a price-to-earnings (or "P/E") ratio of 47.8x Merit Medical Systems, Inc. (NASDAQ:MMSI) may be sending very bearish signals at the moment, given that almost half of all companies in the United States have P/E ratios under 18x and even P/E's lower than 10x are not unusual. However, the P/E might be quite high for a reason and it requires further investigation to determine if it's justified.

Recent times have been advantageous for Merit Medical Systems as its earnings have been rising faster than most other companies. It seems that many are expecting the strong earnings performance to persist, which has raised the P/E. If not, then existing shareholders might be a little nervous about the viability of the share price.

See our latest analysis for Merit Medical Systems

pe-multiple-vs-industry
NasdaqGS:MMSI Price to Earnings Ratio vs Industry May 21st 2025
Want the full picture on analyst estimates for the company? Then our free report on Merit Medical Systems will help you uncover what's on the horizon.
Advertisement

Is There Enough Growth For Merit Medical Systems?

In order to justify its P/E ratio, Merit Medical Systems would need to produce outstanding growth well in excess of the market.

Retrospectively, the last year delivered an exceptional 18% gain to the company's bottom line. Pleasingly, EPS has also lifted 143% in aggregate from three years ago, thanks to the last 12 months of growth. So we can start by confirming that the company has done a great job of growing earnings over that time.

Turning to the outlook, the next three years should generate growth of 12% per annum as estimated by the eleven analysts watching the company. That's shaping up to be similar to the 10% per annum growth forecast for the broader market.

With this information, we find it interesting that Merit Medical Systems is trading at a high P/E compared to the market. It seems most investors are ignoring the fairly average growth expectations and are willing to pay up for exposure to the stock. Although, additional gains will be difficult to achieve as this level of earnings growth is likely to weigh down the share price eventually.

The Key Takeaway

We'd say the price-to-earnings ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.

Our examination of Merit Medical Systems' analyst forecasts revealed that its market-matching earnings outlook isn't impacting its high P/E as much as we would have predicted. When we see an average earnings outlook with market-like growth, we suspect the share price is at risk of declining, sending the high P/E lower. Unless these conditions improve, it's challenging to accept these prices as being reasonable.

It's always necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Merit Medical Systems, and understanding should be part of your investment process.

If P/E ratios interest you, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGS:MMSI

Merit Medical Systems

Designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally.

Excellent balance sheet with acceptable track record.

Advertisement

Weekly Picks

ST
stuart_roberts
UG logo
stuart_roberts on Upside Gold ·

An Undervalued 3.3Moz Gold Project in Canada

Fair Value:CA$5.0776.3% undervalued
83 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative
YA
SOFI logo
Yang_ on SoFi Technologies ·

SoFi Technologies: The Apex Aggregator and the Infrastructure of the Modern Financial System

Fair Value:US$22.9820.4% undervalued
8 users have followed this narrative
0 users have commented on this narrative
3 users have liked this narrative
KO
CSL logo
Kouj on CSL ·

CSL: The Dip Is the Opportunity

Fair Value:AU$1556.7% undervalued
5 users have followed this narrative
0 users have commented on this narrative
2 users have liked this narrative
GA
DHT logo
GavrielH on DHT Holdings ·

DHT Holdings, inc: Strait of Hormuz Risk Amidst US-Israel vs Iran Tensions Spikes VLCC Rates.

Fair Value:US$3648.3% undervalued
2 users have followed this narrative
0 users have commented on this narrative
3 users have liked this narrative

Updated Narratives

CF
CFFF
DRO logo
CFFF on DroneShield ·

DroneShield's Growth Will Drive Revenue Up by 25.39% Amidst New Success

Fair Value:AU$1.36195.6% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
VE
Vestra
PATH logo
Vestra on UiPath ·

UiPath Inc. (PATH): Agentic AI Pivot and Milestone Profits Set the Stage for Q4 Results

Fair Value:US$19.6841.1% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
VE
Vestra
AVAV logo
Vestra on AeroVironment ·

AeroVironment (AVAV): Q3 Earnings Miss Balanced by Record Backlog and BlueHalo Integration

Fair Value:US$28722.8% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

KA
NU logo
kabz2342 on Nu Holdings ·

Nu holdings will continue to disrupt the South American banking market

Fair Value:US$64.376.9% undervalued
51 users have followed this narrative
3 users have commented on this narrative
27 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$59631.9% undervalued
1306 users have followed this narrative
2 users have commented on this narrative
10 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0227.0% undervalued
1102 users have followed this narrative
7 users have commented on this narrative
34 users have liked this narrative